I think, based on previous announcements this means that whilst it is non-small cell lung cancer that is being targeted, TG4010 MAY be effective in treating other cancers.
Can anyone shed light on the announcement. Transgene getting hammered now that announcement has been digested. My interpretation is Transgene will be paying for upcoming tests and only if they are successful will the option be exercised and the $10million option fee be paid? Is this correct?
However that plays out, I cant see any downside for VHL. Trangene getting hammered now because they are going to be paying for the upcoming trial(if i'm reading it right), but is seems the rewards are better for them in the long run. And for VHL, with the trial going ahead and with Transgene in control, it can only be good.
Can anyone confirm that I am interpretting the 'deal' correctly?
VHL Price at posting:
11.2¢ Sentiment: Hold Disclosure: Held
